

Please join us for this industry session,  
financially supported by Takeda,  
during the 36th ECNP Congress

# Management of patients with ADHD and substance use disorders

Monday, October 09, 2023 | 13:00-13:30 CEST  
Centre Convencions Internacional de Barcelona (CCIB), Room 118  
Industry Interactive Discussion: IID02



**Josep Antoni Ramos-Quiroga** and **Wim van den Brink** will discuss how we can optimize multimodal treatment for patients with ADHD and SUD as we consider treatment initiation, dose titration, and nonpharmacological and pharmacological treatment follow-up.



## **JOSEP ANTONI RAMOS-QUIROGA, MD, PHD**

Professor of Psychiatry at  
Universitat Autònoma de Barcelona, Spain, and  
Head of the Department of Psychiatry at the  
Hospital Universitari Vall d'Hebron, Barcelona, Spain




## **WIM VAN DEN BRINK, MD, PHD**

Emeritus Professor of Psychiatry and Addiction at the  
Amsterdam University Medical Centers in Amsterdam,  
the Netherlands, and Co-founder and President of the  
International Collaboration on ADHD and  
Substance Abuse (ICASA)

TOPIC	PRESENTER
Welcome (3 mins)	Josep Antoni Ramos-Quiroga
Management of patients with ADHD and SUD (7 mins)	Wim van den Brink
Panel discussion (18 mins)	Josep Antoni Ramos-Quiroga Wim van den Brink
Conclusions (2 mins)	Josep Antoni Ramos-Quiroga

ADHD, attention deficit hyperactivity disorder; SUD, substance use disorders.

This Industry Interactive Discussion is open to healthcare professionals who attend the 36<sup>th</sup> ECNP Congress.  
This Industry Interactive Discussion has been initiated, organized, and funded by Takeda Pharmaceuticals International AG.  
Takeda Products may be mentioned.

Copyright 2023. Takeda Pharmaceutical Company Limited. All rights reserved. TAKEDA and  are registered trademarks of Takeda Pharmaceutical Company Limited, used under license.

VV-MEDMAT-87927 | Date of preparation: July 2023

